Peptide Inhibits Hepatitis C Virus Replication in Human Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, such as combinatorial use of PEG-interferon and ribavirin, have significant side effects and are only effective in a proportion of patients, and the development of new anti-HCV therapeutics is hindered by the lack of reliable physiological cell culture systems for serum-borne HCV, leading to concerns over extrapolating findings into clinical virus-host interactions.
Innovation Solution
Administration of a peptide with an amino acid sequence having at least 70% identity to DEAQETAVSSHEQD or its variants, derivatives, or fragments, which inhibits HCV replication in subjects, potentially used in combination with other anti-HCV agents, and a pharmaceutical composition comprising this peptide for treating or preventing HCV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments such as PEG-interferon and ribavirin are used, then HCV infection can be treated, but significant side effects occur and effectiveness is limited to only a proportion of patients
Solution Approach 1:
The invention extracts and utilizes a specific peptide sequence (DEAQETAVSSHEQD) from natural sources to create a targeted anti-HCV therapeutic agent, separating the effective antiviral component from the harmful side effects associated with conventional treatments like PEG-interferon and ribavirin
Solution Approach 2:
The peptide-based treatment offers a lower-cost alternative to expensive small molecule HCV-specific enzyme inhibitors, making therapy more accessible while maintaining effectiveness across diverse patient populations including those with different HCV genotypes
2Adaptability or versatility
If small molecule HCV-specific enzyme inhibitors are developed, then new anti-HCV treatment is achieved, but production cost is high and long-term adverse effects require monitoring
Solution Approach 1:
The peptide therapeutic provides a cost-effective alternative to expensive small molecule inhibitors, utilizing naturally derived or synthesizable peptide sequences that can be produced more economically while providing comparable or superior therapeutic benefits across multiple HCV genotypes
3Productivity
If in vitro cell-based culture methods using molecular clones are employed, then HCV can be propagated in cell lines, but the models use non-primary human cells making clinical extrapolation problematic
Solution Approach 1:
The invention uses human adipose-derived stem cells (hADSC) as an intermediary cell type that bridges the gap between easy-to-culture cell lines and difficult-to-obtain primary human hepatocytes, enabling robust viral propagation while maintaining clinical relevance for drug screening and pathogenesis studies
Solution Approach 2:
The hADSC model creates a more accurate copy of in vivo human liver physiology compared to traditional cell line models, allowing researchers to study HCV replication and test therapeutics in a system that better mimics clinical conditions without the logistical challenges of primary cell cultures
Data Source
AI summary
Hepatitis C virus (HCV) infection is a leading cause for liver cirrhosis and hepatocellular carcinoma worldwide2. Current therapeutic regimens are usually poorly tolerated and only effective in a proportion of infected individuals. We discovered a peptide with sequence of DEAQETAVSSHEQD (SEQ ID NO: 1), a fragment of rabbit α1-antiproteinase F, and its derivatives DEAQETAVSSHEQ (SEQ ID NO: 2) and QETAVSSHEQD (SEQ ID NO: 3), significantly inhibit serum-borne HCV replication in hADSC and human hepatocytes.